Literature DB >> 1646732

Contingent tolerance to carbamazepine: a peripheral-type benzodiazepine mechanism.

S R Weiss1, R M Post.   

Abstract

Rats were tested for anticonvulsant responsivity to agents active at central and peripheral-type benzodiazepine receptors before and after they were made tolerant to the anticonvulsant effects of carbamazepine on amygdala-kindled seizures. Tolerance to carbamazepine in this paradigm is a contingent process; it occurs when the drug is administered prior to, but not following the kindled seizure. In animals tolerant to carbamazepine, cross-tolerance was observed to the anticonvulsant effects of PK11195, which is active at peripheral-type benzodiazepine receptors, but not to diazepam, which affects central-type benzodiazepine receptors. In animals treated with carbamazepine after the kindled seizure (not tolerant), no alteration in the anticonvulsant effect of PK11195 was observed. These data extend previous biochemical and pharmacological findings suggesting the importance of peripheral-type benzodiazepine receptor mechanisms in the anticonvulsant effects of carbamazepine and suggest a role for this site in the process of contingent tolerance development.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646732     DOI: 10.1016/0014-2999(91)90031-k

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Peripheral benzodiazepine receptors in platelets of epileptic patients.

Authors:  J G Larkin; P J McKee; G G Thompson; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

2.  Modifications of diazepam binding inhibitor and peripheral benzodiazepine receptors in the lymphocytes of epileptic patients.

Authors:  C Ferrarese; M Perego; C Marzorati; G Bianchi; M Frigo; N Pecora; R Riva; G Moretti; L Frattola
Journal:  Ital J Neurol Sci       Date:  1996-04

Review 3.  Tolerance to the prophylactic effects of carbamazepine and related mood stabilizers in the treatment of bipolar disorders.

Authors:  Robert M Post; Susan R B Weiss
Journal:  CNS Neurosci Ther       Date:  2010-12-16       Impact factor: 5.243

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.